miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod.

Alicia Gonzalez-MartinezRohit PatelBrian C HealyHrishikesh LokhandeAnu PaulShrishti SaxenaMariann Polgar-TurcsanyiHoward L WeinerTanuja Chitinis

Published in: Journal of neuroinflammation (2023)

Our results show differences in miR-548a-3p expression at 6 months after fingolimod start in patients with MS with NEDA-3 at 2 years. These results provide class III evidence of the use of miR-548a-3p as biomarker of NEDA-3 in patients with fingolimod.

Keyphrases

multiple sclerosis
white matter
poor prognosis
binding protein
long non coding rna